Metabolic dysfunction-associated steatotic liver disease (MASLD) is no longer viewed solely as hepatic pathology. Experts now define it as a complex multisystem disorder driven by extrahepatic factors like dysfunctional adipose tissue and systemic inflammation. This paradigm shift demands that clinicians move beyond organ-centric silos to address cardiovascular and metabolic consequences alongside liver health.
Significant diagnostic gaps persist despite advances in non-invasive testing. Current tools struggle to identify the critical tipping point where disease regression becomes unlikely. While fibrosis staging remains relevant, assessing vascular alterations and parenchymal extinction requires specialized metrics not yet available in routine primary care settings. Establishing validated surrogate markers, comparable to HbA1c in diabetes, remains an urgent unmet need for accelerating drug development.
Therapeutic strategies are evolving toward individualized combination therapies rather than monotherapy standards. Because single agents rarely achieve complete remission due to disease heterogeneity, experts recommend optimizing cardiometabolic drivers first. Liver-targeted agents should be added only if response is insufficient. This granular approach acknowledges that MASLD pathophysiology varies significantly between patients with advanced disease versus those with early-stage metabolic dysfunction.
Clinical misconceptions continue to hinder early intervention. Many practitioners still underestimate mild steatosis or rely excessively on the liver's regenerative capacity. However, liver fat serves as a primary indicator of systemic metabolic ill health and increased Type 2 diabetes risk. Global consensus updates presented at EASL 2026, including Baveno VIII guidelines on portal hypertension, aim to harmonize definitions and standardize risk stratification across international healthcare systems.